Cholecystokinin-58 is more potent in inhibiting food intake than cholecystokinin-8 in rats

References

• Smith GP, Gibbs J. The satiating effects cholecystokinin and bombesin-like peptides. In: Smith GP. (ed) Satiation: From the Gut to the Brain. New York: Oxford Publishing, 1998; 97–125.
   Google Scholar
• Gibbs J, Young RC, Smith GP. Cholecystokinin decreases food intake in rats. J Comp PhysiolPsychol 1973; 84: 488–495.
   Google Scholar
• Crawley JN, Rojas-Ramirez JA, Mendelson WB. The role of central and peripheral cholecystokinin in mediating appetitive behaviors. Peptides 1982; 3: 535–538.
   PubMed Web of Science ®Google Scholar
• Kissileff HR, Pi-Sunyer FX, Thornton J, Smith GP. C-terminal octapeptide of cholecystokinin decreases food intake in man. Am J Clin Nutr 1981; 34: 154–160.
   PubMed Web of Science ®Google Scholar
• Morley JE, Levine AS, Bartness TJ, Nizielski SE, Shaw MJ, Hughes JJ. Species differences in the response to cholecystokinin. Ann NY Acad Sci 1985; 448: 413–416.
   PubMed Web of Science ®Google Scholar
• Canova A, Geary N. Intraperitoneal injections of nanogram CCK- 8 doses inhibit feeding in rats. Appetite 1991; 17: 221–227.
   PubMed Web of Science ®Google Scholar
• Le Sauter J, Geary N. Redundant vagal mediation of the synergistic satiety effect of pancreatic glucagon and cholecystokinin in sham feeding rats. JAuton Nerv Syst 1990; 30:13–22.
   PubMedGoogle Scholar
• Linden A, Sodersten P. Relationship between the concentration of cholecystokinin-like immunoreactivity in plasma and food intake in male rats. Physiol Behav 1990; 48: 859–863.
   PubMed Web of Science ®Google Scholar
• Zittel TT, Glatzle J, Kreis ME, et al. C-fos protein expression in the nucleus of the solitary tract correlates with cholecystokinin dose injected and food intake in rats. Brain Res 1999; 846: 1–11.
   PubMed Web of Science ®Google Scholar
• Edwards GL, Ladenheim EE, Ritter RC. Dorsomedial hindbrain participation in cholecystokinin-induced satiety. Am J Physiol 1986; 251: R971 -R977.
   PubMed Web of Science ®Google Scholar
• Crawley JN, Schwaber JS. Abolition of the behavioral effects of cholecystokinin following bilateral radiofrequency lesions of the parvocellular subdivision of the nucleus tractus solitarius. Brain Res 1984; 295: 289–299.
   PubMed Web of Science ®Google Scholar
• Grill HJ, Smith GP. Cholecystokinin decreases sucrose intake in chronic decerebrate rats. Am J Physiol 1988; 254: R853 -R856.
   PubMed Web of Science ®Google Scholar
• Moran TH. Receptor subtype and affinity state underlaying the satiety actions of cholecystokinin. In: Cooper SJ, Clifton PG. (eds) Drug receptorsubtypes and ingestive behaviour. London: Academic Press, 1996; 1–21.
   Google Scholar
• Kreis ME, Zittel TT, Raybould HE, Reeve JR, Grundy D. Prolonged intestinal afferent nerve discharge in response to cholecysto- kinin-58 compared to cholecystokinin-8 in rats. Neurosci Lett 1997; 230: 89–92.
   PubMed Web of Science ®Google Scholar
• Glatzle J, Kreis ME, Kawano K, Raybould HE, Zittel TT. Postprandial neuronal activation in the nucleus of the solitary tract is partly mediated by CCK-A receptors. Am J Physiol 2001; 281: R222 -R229.
   Web of Science ®Google Scholar
• Raybould HE. Capsaicin-sensitive vagal afferents and CCK in inhibition of gastric motor function induced by intestinal nutrients. Peptides 1991; 12: 1279–1283.
   PubMed Web of Science ®Google Scholar
• Eysselein VE, Eberlein GA, Hesse WH, et al. Molecular variants of cholecystokinin after endogenous stimulation in humans: a time study. Am J Physiol 1990; 258: G951 -G957.
   PubMed Web of Science ®Google Scholar
• Reeve Jr JR, Eysselein V, Walsh JH, Ben Avram CM, Shively JE. New molecular forms of cholecystokinin. Microsequence analysis of forms previously characterized by chromatographic methods. J BiolChem 1986; 261: 16392–16397.
   PubMed Web of Science ®Google Scholar
• Reeve Jr JR, Green GM, Chew P, Eysselein VE, Keire DA. CCK- 58 is the only detectable endocrine form of cholecystokinin in rat. Am J Physiol 2003; 285: G255 -G265.
   Web of Science ®Google Scholar
• Raybould HE, Reeve JR. CCK-58: a novel reagent for studying the regulation of cholecystokinin bioactivity. Peptides 1996; 17: 1307–1311.
   PubMed Web of Science ®Google Scholar
• Reeve Jr JR, Wu SV, Keire DA, et al. Differential bile-pancreatic secretory effects of CCK-58 and CCK-8. Am J Physiol 2004; 286: G395 -G402.
   Web of Science ®Google Scholar
• Yamamoto M, Reeve Jr JR, Keire DA, Green GM. Water and enzyme secretion are tightly coupled in pancreatic secretion stimulated by food or CCK-58 but not by CCK-8. Am J Physiol 2005; 288: G866 -G879.
   Web of Science ®Google Scholar
• Turkelson CM, Solomon TE, Bussjaeger L, et al. Chemical characterization of rat cholecystokinin-58. Peptides 1988; 9: 1255–1260.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF. The molecular nature of cholecystokinin in plasma. An in vivo immunosorption study in rabbits. Scand J Gastroenterol 1994; 29: 110–121.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF. How to measure cholecystokinin in tissue, plasma and cerebrospinal fluid. RegulPept 1998; 78: 31–39.
   PubMedGoogle Scholar
• Eysselein VE, Eberlein GA, Hesse WH, Singer MV, Goebell H, Reeve Jr JR. Cholecystokinin-58 is the major circulating form of cholecystokinin in canine blood. J Biol Chem 1987; 262: 214–217.
   PubMed Web of Science ®Google Scholar
• Liddle RA, Goldfine ID, Williams JA. Bioassay of plasma cholecystokinin in rats: effects of food, trypsin inhibitor, and alcohol. Gastroenterology 1984; 87: 542–549.
   PubMed Web of Science ®Google Scholar
• Chang TM, Thagesen H, Lee KY Roth FL, Chey WY Canine vagus nerve stores cholecystokinin-58 and -8 but releases only cholecystokinin-8 upon electrical vagal stimulation. Regul Pept 2000; 87:1–7.
   PubMedGoogle Scholar
• Eysselein VE, Reeve Jr JR, Eberlein G. Cholecystokinin-gene structure, and molecular forms in tissue and blood. Z Gastroenterol 1986; 24: 645–659.
   PubMed Web of Science ®Google Scholar
• Sun G, Chang TM, Xue WJ, Wey JF, Lee KY, Chey WY. Release of cholecystokinin and secretin by sodium oleate in dogs: molecular form and bioactivity. Am J Physiol 1992; 262: G35 -G43.
   PubMed Web of Science ®Google Scholar
• Cantor P, Rehfeld JF. Cholecystokinin in pig plasma: release of components devoid of a bioactive -COOH terminus. Am J Physiol 1989; 256: G53 -G61.
   PubMed Web of Science ®Google Scholar
• Eysselein VE, Bottcher W, Kauffman Jr GL, Walsh JH. Molecular heterogeneity of canine cholecystokinin in portal and peripheral plasma. RegulPept 1984; 9: 173–185.
   PubMed Web of Science ®Google Scholar
• Gores GJ, LaRusso NF, Miller LJ. Hepatic processing of cholecystokinin peptides. I. Structural specificity and mechanism of hepatic extraction. Am J Physiol 1986; 250: G344 -G349.
   PubMed Web of Science ®Google Scholar
• Greenberg D, Smith GP, Gibbs J. Infusion of CCK-8 into hepatic- portal vein fails to reduce food intake in rats. Am J Physiol 1987; 252: R1015 -R1018.
   PubMed Web of Science ®Google Scholar
• Strunz UT, Thompson MR, Elashoff J, Grossman MI. Hepatic inactivation of gastrins of various chain lengths in dogs. Gastroenterology 1978; 74: 550–553.
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Eberlein GA, Reeve Jr JR, et al. Comparison of clearance and metabolism of infused cholecystokinins 8 and 58 in dogs. Gastroenterology 1993; 105: 1732–1736.
   PubMed Web of Science ®Google Scholar
• Reeve Jr JR, McVey DC, Bunnett NW, et al. Differences in receptor binding and stability to enzymatic digestion between CCK-8 and CCK-58. Pancreas 2002; 25: e50–55.
   PubMed Web of Science ®Google Scholar
• Reeve JR, Eysselein VE, Rosenquist G, et al. Evidence that CCK- 58 has structure that influences its biological activity. Am J Physiol 1996; 270: G860 -G868.
   PubMed Web of Science ®Google Scholar
• Keire DA, Solomon TE, Reeve Jr JR. Identical primary sequence but different conformations of the bioactive regions of canine CCK-8 and CCK-58. Biochem BiophysRes Commun 1999; 266: 400–404.
   PubMed Web of Science ®Google Scholar
• Kopin AS, Mathes WF, McBride EW, et al. The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight. J Clin Invest 1999; 103: 383–391.
   PubMed Web of Science ®Google Scholar
• Liddle RA, Goldfine ID, Rosen MS, Taplitz RA, Williams JA. Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest 1985; 75: 1144–1152.
   PubMed Web of Science ®Google Scholar
• Hagiwara M, Ohuchi E, Hongo K, et al. Pharmacological activity of angiotensin-II modified by tyrosine sulfation. Jpn J Pharmacol 1990; 52: 493–495.
   PubMedGoogle Scholar
• Eysselein VE, Eberlein GA, Schaeffer M, et al. Characterization of the major form of cholecystokinin in human intestine: CCK-58. Am J Physiol 1990; 258: G253 -G260.
   PubMed Web of Science ®Google Scholar
• Lieverse RJ, Jansen JB, Masclee AA, Lamers CB. Satiety effects of a physiological dose of cholecystokinin in humans. Gut 1995; 36: 176–179.
   PubMed Web of Science ®Google Scholar
• Glatzle J, Wang Y, Adelson DW, et al. Chylomicron components activate duodenal vagal afferents via a cholecystokinin A receptor- mediated pathway to inhibit gastric motor function in the rat. J Physiol 2003; 550: 657–664.
   PubMed Web of Science ®Google Scholar